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With the use of chemistry-based artificial restriction DNA 
cutter (combination of Ce(IV)/EDTA and a pair of pcPNA), 
both an antibiotic-resistance gene and a fluorescent reporter 
protein gene were incorporated into the targeted site through 
homologous recombination in human cells. 10 
Homologous recombination is one of the most powerful methods 
to manipulate genomes, and has been attracting significant 
interests of chemists, biochemists, and biologists. The site of 
recombination can be dictated by DNA cutter, since a double 
strand break (DSB) at target site notably activates the DNA repair 15 
machinery there.1 Various kinds of protein-based DNA cutters 
have been reported to promote homologous recombination. 
Typical examples are ZFN2-5 and TALEN,6-8 in which a non-
specific nuclease domain of FokI restriction enzyme was fused 
with either tandemly-assembled zinc finger proteins or a 20 
transcription activator-like effector. Homing endonucleases 
which recognize long sequences were engineered.9-12 Recently, a 
CRISPR/CAS method based on RNA-guided DNA scission was 
also developed as a new gene manipulation method.13-15 However, 
few reports have been made on completely chemistry-based tools 25 
for homologous recombination. 
Recently, we prepared artificial restriction DNA cutter 
(ARCUT), which is composed of Ce(IV)/EDTA complex and a 
pair of pseudo-complementary peptide nucleic acid (pcPNA) 
strands and never involves either proteins or other 30 
biomolecules.16,17 PNA is a synthetic DNA analog which is 
formed from poly[N-(2-aminoethyl)glycine] backbone. The site 
of selective scission of this cutter is a priori determined by 
Watson-Crick base-pairings between the pcPNA strands and the 
DNA substrate. Moreover, this cutter can be rapidly and easily 35 
prepared by well-established chemical method. It was also shown 
that DSB introduced by ARCUT is satisfactorily recognized by 
the repair system in human cells and stimulates the homologous 
recombination.18,19 For example, the gene of blue fluorescent 
protein (BFP) was converted in the cells to that of highly relevant 40 
enhanced green fluorescent protein (EGFP). This mutation 
involved the replacement of the sequence at the chromophore-
forming site of BFP with another sequence of the same length 
which is presented by the EGFP gene in the donor DNA. In this 
paper, ARCUT-mediated homologous recombination is used to 45 
insert various genes to predetermined sites in human cells. The 
efficiency of insertion is sufficiently high, although the DNA 
donors employed here are far longer than those for the mutation 
experiments. The inserted neomycin-resistance gene (Neor) and 
DsRed2 gene are successfully expressed to show the expected 50 
functions (the antibiotic resistance or fluorescence emission). 
Versatile utility of ARCUT for gene manipulation has been 
further indicated. 
 
Fig. 1 Schemes for the insertion of target gene into a plasmid in human 55 
cells through homologous recombination. (a) Insertion of neomycin-
resistance gene (Neor). The BFP gene in pBFP-Ampr  was cut by ARCUT 
and incorporated into human cells, together with a donor involving IRES-
Neor sequence. The cells growing in the presence of G418 are selected 
and analyzed. (b) Insertion of DsRed2 gene. The donor involves 2A-60 
DsRed2 sequence, and thus the cells emitting red fluorescence are 
counted.  
 
 Outline of the present study is shown in Fig. 1. A BFP gene is 
placed in a plasmid pBFP-Ampr, which has no neomycin-65 
resistance gene. First, the BFP gene is cut by ARCUT at the 
chromophore-forming site. Then, this DNA product is introduced 
into human cells, together with a donor involving either IRES-
Neor (Fig. 1a) or 2A-DsRed2 sequence (Fig.1b). In these donors, 
either Neor or DsRed2 gene has no promoter and thus cannot be 70 
directly expressed. The homology region in the donor covers 
This journal is © The Royal Society of Chemistry [year] [journal], [year], [vol], 00–00  |  1 
 
about 190 bp of the upstream of the ARCUT scission site and 
510-540 bp of its downstream. When the corresponding 
homologous recombination occurs in the human cells, IRES-Neor 
gene cassette (1608 bp) or 2A-DsRed2 gene cassette (754 bp) is 
inserted to the plasmid. In the upstream of Neor, IRES (internal 5 
ribosome entry site; 495 bp) is placed to recruit the ribosome in 
the cells and allow the Neor to be translated independently from 
the typical cap-dependent translation pathway (Fig. 1a).20 On the 
other hand, 2A peptide sequence is placed in the upstream of the 
DsRed2 gene (Fig. 1b). This short peptide (21 amino acids) 10 
shows self-cleaving activity during ribosomal protein synthesis, 
and can be an attractive alternative to IRES.21 The incorporation 
and expression of the Neor gene can be detected in terms of the 
resistance of the human cells to G418, whereas the DsRed2 gene 
in the cells should emit the red fluorescence. Further details on 15 
the constructs are shown in Fig. S1.  
 
Fig. 2 Survival rates of variously treated human cells in the medium 
containing G418. The red line corresponds to the experiment in which 
pBFP-Ampr plasmid was cut by the ARCUT and incorporated into the 20 
cells together with the donor involving the IRES-Neor sequence (see Fig. 
1a). As references, pBFP-Ampr which was not treated by the ARCUT was 
lipofected into the cells with (blue) or without the donor (purple). The 
green line is for the experiment where only the donor was transfected to 
the cells in the absence of pBFP-Ampr. These cells were cultured in the 25 
presence of 1.2 mg/ml of G418. 
 
With the use of the ARCUT presented in Fig. S2, the pBFP-
Ampr plasmid was selectively cut at the chromophore-forming 
site in the BFP gene. Then, the product of this ARCUT scission 30 
was incorporated into Flp-in 293TM cells (Life Technologies) by 
lipofection using FuGENE HD (Promega), together with the 
donor DNA involving the IRES-Neor sequence (Fig. 1a). The 
cells were cultured in the medium containing G418. This 
antibiotic inhibits protein elongation event of ribosome in 35 
eukaryote and is used as a selective antibiotic for neomycin-
resistance gene encoding aminoglycoside 3’-phosphotransferase. 
As shown by the red line in Fig. 2, thus treated cells are much 
more resistant to G418, and even after 7 days, significant 
proportions of the cells are still alive. With the lipofection of (i) 40 
the plasmid only, (ii) the donor only, or (iii) the diluent only, 
however, all the cells died under the same conditions. By 
introducing the ARCUT scission product and the IRES-Neor 
donor, the targeted homologous recombination successfully 
occurred in the human cells to insert the Neor gene to the DSB 45 
site. Consistently, the survival rate of the cells was much lower 
when pBFP-Ampr was lipofected into the cells without being cut 
by the ARCUT, together with the donor DNA (the blue line). 
Apparently, the ARCUT-induced DSB notably promotes the 
targeted insertion of the IRES-Neor gene cassette (1608 bp) 50 
through homologous recombination. The gradual decrease in the 
survival rate even with the introduction of ARCUT 
product/IRES-Neor donor is due to the fact that the Flp-in 293TM 
cells have no plasmid-duplicating activity and thus the fraction of 
the cells containing the recombinant plasmid(s) decreases as the 55 
cell division proceeds. 
 The efficiency of gene insertion by ARCUT was more 
directly measured by inserting DsRed2 gene as fluorometric 
probe (Fig. 1b). Into 293T cells, the ARCUT-scission product and 
the donor involving the 2A-DsRed2 sequence were 60 
electroporated. The electroporation was achieved on a NeonTM 
Transfection System from Life Technologies (Square wave, Pulse 
Voltage 1150 V, Pulse Width 20 ms, and Pulse Number 2). After 
36 hours, the cells were analyzed by flow cytometry (Guava 
EasyCyte Plus, Millipore). As shown in Fig. 3a (and also in Fig. 65 
S3a), many cells emit red fluorescence, only when the pBFP-
Ampr was first cut with the ARCUT and introduced to the cells 
together with the 2A-DsRed2 donor (the left bar). When the 
intact pBFP-Ampr and the donor are introduced to the cells (No 
cut), the fluorescent cells are marginal (the middle bar). Upon the 70 
introduction of the donor DNA alone (without the pBFP-Ampr), 
few fluorescent cells were observed as expected (the right bar). 
The importance of the site-selective scission by the ARCUT for 
the present insertion was further evidenced. The sequencing 
experiments were also consistent with the designed gene insertion 75 
(data not presented).  
Fig. 3 (a) Evaluation of the insertion efficiency by flow cytometry for the 
ARCUT-mediated insertion of DsRed2 gene using the 2A-DsRed2 donor 
(according to Fig. 1b). In (b), the efficiency of ARCUT-mediated 
mutation (conversion of BFP gene to EGFP gene) under comparable 80 
conditions is presented for the purpose of comparison (see the text for 
details). In both (a) and (b), the bars “Not cut” are for the experiments 
where the plasmid was not treated with ARCUT and transfected into the 
cells together with the corresponding donor. In the bars “Donor”, only the 
donor (without the plasmid) was transfected into the cells. 85 
 
It has now been concluded that both the insertion of the whole 
of a gene and the mutation (replacement of rather short sequence 
in a gene) can be promoted by ARCUT-mediated homologous 
recombination. Thus, we decided to compare the efficiencies of 90 
these two reactions under comparable conditions. For the 
mutation experiment, the conversion of BFP to EGFP was 
chosen.18,19 The same amounts of the ARCUT-scission product of 
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pBFP-Ampr  and the donor DNA were used (4.8 nM and 34 nM, 
respectively), and the lengths of the homology region were also 
made similar (compare b and c in Fig. S1). As shown in Fig. 3b, 
the mutation (the conversion of BFP to EGFP) occurred slightly 
more efficiently than the insertion of DsRed2 in 24 hours. 5 
However, the difference is rather small (only 4 fold here), when it 
is considered that the 2A-DsRed2 insert is almost 750 bp long 
and could make unfavorable steric effects on the homologous 
recombination.  
In conclusion, desired genes can be successfully inserted to 10 
targeted site through ARCUT-mediated homologous 
recombination. This fact indicates further potentiality of this 
chemistry-based DNA cutter as tools for genome manipulation. 
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